" class="no-js "lang="en-US"> Martin Akerman - Medtech Alert
Friday, October 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Martin Akerman

Martin Akerman

About Martin Akerman

Transparency and reproducibility are shared values of people and machines. Innovation is more likely when predictions can be explained and validated

Related Story

Artificial Intelligence

 Envisagenics Raises Series A Financing to Scale its AI-powered RNA Splicing Drug Discovery Platform | Pharmtech Focus

Envisagenics Raises Series A Financing to Scale its AI-powered RNA Splicing Drug Discovery Platform

September 30 2021

Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA […]